← back to search

Cedric Francois

Apellis Pharmaceuticals (United States) · US
Area of research
Immunology · Transplantation
Research interest
Research interests include Complement system in diseases, Organ and Tissue Transplantation Research, Blood groups and transfusion, and Coagulation, Bradykinin, Polyphosphates, and Angioedema.
h-index
22
citations
2,565
works
68
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
New England Journal of Medicine 2025cited by 21position: middledoi
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
The Lancet 2023cited by 420position: middledoi
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Ophthalmology 2019cited by 505position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

— · 1 papers (2019–2019)Lawrence J. Singerman · Case Western Reserve University1 papers (2019–2019)Jeffrey S. Heier · Wills Eye Hospital1 papers (2019–2019)F Grossi · University of Helsinki1 papers (2019–2019)Pascal Deschatelets · Apellis Pharmaceuticals (United States)1 papers (2019–2019)— · 1 papers (2019–2019)— · 1 papers (2019–2019)— · 1 papers (2019–2019)Charles C. Wykoff · Nune Eye Hospital1 papers (2019–2019)Robert Y. Kim · University of Alabama at Birmingham1 papers (2019–2019)— · 1 papers (2019–2019)David S. Boyer · University of Southern California1 papers (2019–2019)Jason S. Slakter · NYU Langone Health1 papers (2019–2019)Bernhard H. F. Weber · University of Regensburg1 papers (2019–2019)Felix Graßmann · MSH Medical School Hamburg – University of Applied Sciences and Medical University1 papers (2019–2019)Philip J. Rosenfeld · University of Miami1 papers (2019–2019)David M. Brown · Tennessee Retina1 papers (2019–2019)— · 1 papers (2019–2019)David Liao · Cedars-Sinai Medical Center1 papers (2019–2019)Ramiro Ribeiro · Apellis Pharmaceuticals (United States)1 papers (2019–2019)